Literature DB >> 31272065

Immunization using male germ cells and gametes as rich sources of cancer/testis antigens for inhibition of 4T1 breast tumors' growth and metastasis in BALB/c mice.

Ashkan Safavi1, Amirhosein Kefayat2, Fatemeh Ghahremani3, Elham Mahdevar4, Jamal Moshtaghian5.   

Abstract

Recently cancer/testis antigens (CTA) have gained lots of attention as targets of immune therapy. However, the therapeutic efficacy of the CTAs single-antigen vaccines is not satisfying due to tumor heterogenicity. Therefore, many studies have focused on the enhancement of their efficacy by utilizing rich sources of tumor-associated antigens for anti-cancer vaccination. In the present study, the testicular germ cells and sperm cells as well-known sources of cancer/testis antigens were investigated for anti-4T1 breast cancer vaccination in BALB/c mice. The testicular germ cells (TGCs) and sperm cells were isolated from male BALB/c mice. The definite number of cells were homogenized and mixed with Bacillus Calmette-Guerin (BCG) for vaccination of female BALB/c mice. The treatment groups underwent 3 times of immunizations with one-week intervals and one week after the last injection, all groups were injected with 4T1 cancer cells. The TGCs + BCG (259.7 ± 39 mm3) and Sperm + BCG (426 ± 52 mm3) groups exhibited a significant decrease in the tumors' volume in comparison with BCG (641.3 ± 102 mm3) and no-treatment (788.1 ± 117 mm3) groups. Therefore, the TGCs + BCG immunized mice had the smallest tumors in comparison with all groups (P < 0.05). Also, the vital organs of TGCs + BCG (lungs: 6.8 ± 2, liver: 10.1 ± 2) immunized mice exhibited lowest metastatic burden in comparison with the Sperm + BCG (lungs: 13.5 ± 3, liver: 21.1 ± 4), BCG (lungs: 24.3 ± 4, liver: 33 ± 4), and no-treatment (lungs: 26.5 ± 6, liver: 37.3 ± 3) groups. These observations were inconsistent with the tumor-bearing mice survival evaluations as the TGCs + BCG group had longer mean survival time (79.6 ± 12 days) in comparison with other groups (no-treatment: 49.8 ± 8, BCG: 50.5 ± 10, BCG + Sperm: 64.6 ± 7 days). Therefore, TGCs can be a potential source of antigens for the anti-breast cancer immunization and more investigations are necessary.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer/testis antigens; Sperm; Testicular germ cells; Vaccination

Mesh:

Substances:

Year:  2019        PMID: 31272065     DOI: 10.1016/j.intimp.2019.105719

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  3 in total

1.  Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model.

Authors:  Ashkan Safavi; Amirhosein Kefayat; Elham Mahdevar; Fatemeh Ghahremani; Navid Nezafat; Mohammad Hossein Modarressi
Journal:  Hum Vaccin Immunother       Date:  2020-06-04       Impact factor: 3.452

2.  Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies.

Authors:  Mary Zhang; Julie A Hong; Tricia F Kunst; Colleen D Bond; Cara M Kenney; Cheryl L Warga; Javier Yeray; Min-Jung Lee; Akira Yuno; Sunmin Lee; Markku Miettinen; R Taylor Ripley; Chuong D Hoang; Sacha Gnjatic; Jane B Trepel; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2021-07

3.  Induction of Immunogenic Cell Death by Photodynamic Therapy Mediated by Aluminum-Phthalocyanine in Nanoemulsion.

Authors:  Mosar Corrêa Rodrigues; Wellington Tavares de Sousa Júnior; Thayná Mundim; Camilla Lepesqueur Costa Vale; Jaqueline Vaz de Oliveira; Rayane Ganassin; Thyago José Arruda Pacheco; José Athayde Vasconcelos Morais; João Paulo Figueiró Longo; Ricardo Bentes Azevedo; Luis Alexandre Muehlmann
Journal:  Pharmaceutics       Date:  2022-01-14       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.